In cryopreserved peripheral T cells from lymphoma patients in our bispecific CD20/CD19 CAR T clinical trial, OMI could identify early metabolic stress and allowed gating of metabolically fit cells associated with post-thaw viability. This evidence concerns the gene CD19 and lymphoma.